Pyrazolo[4,3-d]pyrimidine Derivatives as a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor for the Treatment of Anemia.

Inhibition of hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) promotes erythropoietin (EPO) production by stabilizing the HIFα subunit. Thieno[2,3-d]pyrimidine 8 identified based on X-ray crystal structure analysis was optimized to lead to the discovery of pyrazolo[4,3-d]pyrimidine 13 as the lead compound of orally bioavailable HIF-PHD inhibitors. Conversion of the benzyl moiety in 13 gave pyrazolopyrimidine 19 with high solubility and bioavailability, which increased hemoglobin levels in anemic model rats after repeated oral administration. It was shown that pyrazolo[4,3-d]pyrimidine derivatives are promising therapeutic agents for renal anemia through the inhibition of HIF-PHD.

[1]  Anders Poulsen,et al.  Targeting the Bacterial Epitranscriptome for Antibiotic Development: Discovery of Novel tRNA-(N1G37) Methyltransferase (TrmD) Inhibitors. , 2019, ACS infectious diseases.

[2]  C. Chiu,et al.  Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia. , 2018, ACS medicinal chemistry letters.

[3]  G. Fields,et al.  Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study. , 2018, Bioorganic & medicinal chemistry.

[4]  K. Fukase,et al.  Highly Efficient Coupling of Unstable Bicyclic Pyrimidines and Pyrazoles under Basic Conditions, and its Application to the Synthesis of Pharmaceutical Compounds , 2018, Synlett.

[5]  J. Keldenich,et al.  Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia , 2018, ChemMedChem.

[6]  K. Read,et al.  2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure–Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization , 2018, ACS infectious diseases.

[7]  K. Fukui,et al.  Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia. , 2017, ACS medicinal chemistry letters.

[8]  A. Ayscough,et al.  1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction. , 2017, Journal of Medicinal Chemistry.

[9]  Jeffrey T. Kuethe,et al.  Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia. , 2016, Journal of medicinal chemistry.

[10]  A. Rastogi,et al.  Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. , 2016, Journal of the American Society of Nephrology : JASN.

[11]  Mukul R Jain,et al.  Recent Developments in HIF Prolyl Hydroxylase Inhibitors , 2015 .

[12]  Minoru Ishikawa,et al.  Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.

[13]  R. Schmieder,et al.  Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. , 2010, Journal of the American Society of Nephrology : JASN.

[14]  M. Nangaku,et al.  The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease , 2010, Nature Reviews Nephrology.

[15]  Y. Hashimoto,et al.  beta-Naphthoflavone analogs as potent and soluble aryl hydrocarbon receptor agonists: improvement of solubility by disruption of molecular planarity. , 2010, Bioorganic & medicinal chemistry.

[16]  ウー シェンデ,et al.  Prolyl hydroxylase inhibitors and methods of use , 2007 .

[17]  デューク・エム・フィッチ,et al.  Prolyl hydroxylase inhibitors , 2007 .

[18]  Tetsuhiro Tanaka,et al.  Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. , 2003, Journal of the American Society of Nephrology : JASN.

[19]  B. Astor,et al.  Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). , 2002, Archives of internal medicine.

[20]  D. J. Bull,et al.  Structure-activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (glycine site) receptor antagonists. 1. Heterocyclic substituted 5-alkyl derivatives. , 2001, Journal of medicinal chemistry.

[21]  M. Rudnick,et al.  Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  K. Koch.  [The treatment of renal anemia]. , 1989, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin.